Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Vemurafenib in BRAF-positive Juvenile Refractory Histiocytosis
2024-515805-25-00Phase 2Authorised
- Sponsor
- Institute of Mother and Child
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in histiocytosis, sponsored by Institute of Mother and Child. Primary endpoints: Event-free survival (EFS), Safety - adverse events and 2 more. Planned start May 2021; status: authorised.
02
Drugs
vemurafenib
03
Conditions
histiocytosis
Beyond the preview
Go deeper on 2024-515805-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515805-25-00.